Condition 1: Withdrawal syndrome. Condition 2: Craving. Mental and behavioural disorders due to use of opioids Mental and behavioural disorders due to use of opioids
Conditions
Interventions
Intervention 1: Group1: one time 40 IUs intranasal Oxytocin(Pitocin
) from NOVARTIS company. Intervention 2: Group2 : one time 40 IUs intranasal saline.
Treatment - Drugs
Group1: one time 40 IUs intranasal Oxytocin(Pitocin
) from NOVARTIS company
Group2 : one time 40 IUs intranasal saline
Sponsors
Vice chancellor for research Kashan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Subjects must meet DSM-IV criteria for current heroin dependence ( within the past six months). Subjects must be at the beginning of treatment period and must abstain from heroin for at least three days prior to testing. patients willing to participate in the intervention- The age range of subjects must be between 20 to 60 years old. Subjects must be literate. Exclusion Criteria : Women who are pregnant, nursing or of childbearing potential and positive of pregnancy test. Subjects with evidence of or a history of significant hematological, endocrine, cardiovascular, pulmonary, renal, drug allergy or neurological disease including diabetes, as these conditions may affect physiological/subjective responses. Subjects with Addison's disease, Cushing's disease or other diseases of the adrenal cortex likely to affect hormonal/neuroendocrine status. Subjects with current major depressive disorder, bipolar or post-traumatic stress disorder as these disorders are associated with characteristic changes in stress response. Subjects receiving synthetic glucocorticoid therapy, any exogenous steroid therapy within one month of test session. Subjects taking any psychotropic medications, including SSRI's or other antidepressants, opiates or opiate antagonists as these medicines may affect the test response. Subjects with any acute illness or fever. - positive urine tests indicating abuse of any abuse or stimulant.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptom of withdrawal syndrome of heroin. Timepoint: before and after receiving oxytocin. Method of measurement: clinical opioid withdrawal scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical opiod craving. Timepoint: before and after receiving oxytocin. Method of measurement: clinical opioid craving scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMina Moeini
Kashan University of Medical Sciences
Outcome results
None listed